Global Neurodiagnostics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Technology;
Neuroimaging Technologies, In Vitro Diagnostics, and Neuro informatics.By End Use;
Hospitals and Clinics.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Neurodiagnostics Market (USD Million), 2021 - 2031
In the year 2024, the Global Neurodiagnostics Market was valued at USD 7,922.53 million. The size of this market is expected to increase to USD 13,316.00 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.7%.
The global neurodiagnostics market has witnessed significant growth in recent years, driven by rising neurological disorders and the need for early, precise diagnosis. Neurodiagnostic tools and techniques, including imaging systems, electroencephalography (EEG), magnetoencephalography (MEG), and neuroinformatics, are crucial in detecting, monitoring, and treating neurological conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and brain injuries. With advancements in technology, these tools have become more accurate and accessible, facilitating the development of new diagnostic methods and contributing to the market's growth. Factors such as the aging population, increased healthcare spending, and growing awareness of neurological disorders further fuel this expansion.
One of the major drivers in the neurodiagnostics market is the rise in technological innovation, particularly in imaging systems like MRI and CT scans. These systems provide high-resolution, detailed images that help clinicians understand complex neurological structures and diagnose various brain-related disorders more effectively. Additionally, non-invasive techniques like EEG and MEG have advanced significantly, allowing for safer and quicker diagnostics. The integration of artificial intelligence and machine learning in neurodiagnostic technologies is also revolutionizing the market, as these technologies enhance diagnostic accuracy, predict potential health risks, and allow for personalized treatment plans. This innovation is increasingly being adopted by healthcare providers worldwide, contributing to the market's steady growth.
Despite the growth potential, the neurodiagnostics market faces several challenges, including high costs of advanced diagnostic equipment and limited access in developing regions. Additionally, a shortage of skilled professionals to operate sophisticated diagnostic machinery remains a barrier, especially in low-income areas where healthcare resources are constrained. Nonetheless, many companies and governments are investing in training initiatives and improving healthcare infrastructure to address these challenges. The global neurodiagnostics market is anticipated to continue expanding as it adapts to these obstacles, benefiting from increased research funding and strategic partnerships between healthcare institutions and technology providers. As the demand for effective diagnostic solutions rises, the neurodiagnostics market is positioned to play a vital role in addressing the global burden of neurological disorders.
Global Neurodiagnostics Market Recent Developments
-
In March 2024, Philips, in partnership with SyntheticMR, introduced an AI-based quantitative brain imaging system. The partnership is expected to help in the detection and analysis of several brain conditions, including multiple sclerosis, traumatic brain injuries, and dementia.
-
In March 2024, Neurophet introduced an AI-powered brain imaging analysis technology at AD/PD 2024. The technology is expected to help in the analysis of brain atrophy and white matter hyperintensities, which are found in the brain MRI of patients suffering from Alzheimer's disease
Segment Analysis
The global neurodiagnostics market can be segmented by technology, application, end-user, and region, each of which plays a critical role in shaping the industry landscape. By technology, the market includes imaging systems (such as MRI and CT scans), electroencephalography (EEG), electromyography (EMG), and other tools like near-infrared spectroscopy (NIRS) and magnetoencephalography (MEG). Among these, imaging systems hold the largest market share due to their widespread application in diagnosing complex neurological disorders with high accuracy. Recent advancements, especially in MRI and CT technology, have improved diagnostic precision, further boosting this segment. Meanwhile, EEG and EMG are gaining traction for their non-invasive nature and suitability in identifying brain abnormalities, such as epilepsy, making them valuable in neurology clinics and research settings.
In terms of application, the neurodiagnostics market is segmented into diseases like Alzheimer's, Parkinson's, epilepsy, and stroke, as well as neurodegenerative and other neurovascular disorders. Alzheimer’s and Parkinson’s disease hold a substantial share due to the increasing prevalence of these conditions worldwide. With an aging population, neurodegenerative diseases are on the rise, leading to higher demand for diagnostic tools that facilitate early detection and intervention. Additionally, the epilepsy segment is expected to grow as more advanced neurodiagnostic techniques emerge to aid in precise diagnosis and tailored treatment plans. The demand for effective tools in stroke diagnosis is also significant, as quick and accurate diagnosis is essential for better patient outcomes.
The end-user segmentation of the neurodiagnostics market includes hospitals, diagnostic centers, and research laboratories. Hospitals represent the largest share due to the high patient inflow and the availability of advanced neurodiagnostic equipment. Diagnostic centers are seeing growth as they become increasingly specialized, providing quicker and more cost-effective diagnostic services. Research laboratories also form a critical segment, driven by growing research funding for neurological disorders and the need for specialized diagnostic tools in clinical studies. Regionally, North America dominates the neurodiagnostics market, owing to its advanced healthcare infrastructure and high adoption of new technologies. However, Asia-Pacific is expected to experience the fastest growth due to rising healthcare awareness, increasing government investments, and a growing prevalence of neurological disorders. Each of these segments reflects the market’s potential for growth as neurodiagnostic technologies continue to evolve to meet the complex needs of neurological care.
Global Neurodiagnostics Segment Analysis
In this report, the Global Neurodiagnostics Market has been segmented by Technology, End user and Geography.
Global Neurodiagnostics Market, Segmentation by Technology
The Global Neurodiagnostics Market has been segmented by Technology into Neuroimaging Technologies, In Vitro Diagnostics, and Neuro informatics.
The global neurodiagnostics market, segmented by technology into neuroimaging technologies, in vitro diagnostics (IVD), and neuroinformatics, reflects the growing diversity and sophistication in diagnostic tools for neurological conditions. Neuroimaging technologies, which include MRI, CT, PET, and other advanced imaging systems, hold a significant share of the market. These technologies allow for high-resolution, detailed imaging of the brain, essential for diagnosing and understanding complex neurological disorders such as Alzheimer's disease, multiple sclerosis, and brain injuries. MRI and CT scans are particularly prevalent due to their high accuracy and wide accessibility in hospitals and diagnostic centers, and continuous innovations in imaging technology are making these tools more precise and less invasive, driving further adoption.
In vitro diagnostics (IVD) is a crucial segment within neurodiagnostics, involving laboratory-based tests that analyze biological samples (like blood and cerebrospinal fluid) to detect biomarkers associated with neurological conditions. The IVD segment is gaining traction due to the increasing demand for early and accurate diagnosis of conditions such as neurodegenerative diseases and infections affecting the central nervous system. Biomarker research has opened new pathways in diagnosing and monitoring diseases like Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). These tests offer insights into disease mechanisms, progression, and therapeutic responses, making IVD an invaluable tool for personalized treatment plans and preventive healthcare strategies. With advancements in molecular diagnostics, the IVD segment is expected to grow rapidly, enabling non-invasive and early-stage diagnostics.
Neuroinformatics, the third major segment, focuses on the integration of data science and neurology, combining brain imaging, genetic information, and computational tools to enhance diagnostic capabilities. Neuroinformatics plays a critical role in managing and analyzing large volumes of neurological data, which is essential for understanding complex brain disorders. With the rise of artificial intelligence (AI) and machine learning (ML) in healthcare, neuroinformatics is evolving, enabling predictive analytics and personalized medicine. By analyzing patterns and correlations within neurological data, neuroinformatics helps clinicians make more accurate diagnoses and tailor treatments based on individual patient profiles. This segment is expected to see substantial growth as AI and big data analytics become more embedded in neurodiagnostic processes, enhancing the overall efficiency and precision of neurological care. Together, these segments reflect the multifaceted approach of the neurodiagnostics market in addressing diverse diagnostic needs across neurological healthcare.
Global Neurodiagnostics Market, Segmentation by End user
The Global Neurodiagnostics Market has been segmented by End User into Hospitals and clinics.
The global neurodiagnostics market, segmented by end-user into hospitals and clinics, reveals significant insights into how neurological diagnostics are being utilized across different healthcare settings. Hospitals represent the largest segment, driven by the high patient influx, advanced infrastructure, and availability of specialized neurodiagnostic equipment such as MRI, CT, and EEG machines. Hospitals often cater to complex neurological cases, including trauma, stroke, and degenerative diseases, where comprehensive diagnostics are essential for effective treatment. Additionally, hospitals frequently possess dedicated neurology departments staffed with specialists, which allows for a more robust application of neurodiagnostic tools. The integration of advanced imaging systems and dedicated neurology units in hospitals further boosts this segment’s dominance in the neurodiagnostics market.
Clinics, while generally smaller in scale, are rapidly becoming crucial players in the neurodiagnostics market. These facilities provide accessible, community-based care and are increasingly investing in neurodiagnostic equipment to cater to outpatient neurological cases and early-stage diagnostics. Clinics offer a more patient-centered approach, often handling less complex cases such as mild cognitive impairments, migraine, and routine neurological screenings. The use of portable and cost-effective neurodiagnostic tools, like EEG and EMG devices, is becoming more common in clinics, allowing for preliminary assessments before referring patients to hospitals if needed. Furthermore, advancements in telemedicine and digital diagnostics are enabling clinics to expand their diagnostic capabilities, providing patients in remote areas with access to specialized neurodiagnostic consultations and treatments.
As the demand for neurological care rises, both hospitals and clinics are experiencing growth, though with different emphases. Hospitals remain vital for intensive diagnostics and treatment, particularly for acute or complex neurological conditions. However, the trend toward preventive care and early detection is benefiting clinics, as patients increasingly seek diagnostic evaluations outside of hospital settings. This shift is supported by emerging technologies, such as mobile EEG devices and tele-neurology platforms, that allow clinics to expand their neurodiagnostic offerings without the need for large-scale infrastructure. Both end-user segments are essential to the neurodiagnostics market’s growth, complementing each other in providing a comprehensive continuum of care. As healthcare systems worldwide aim to enhance access to neurological diagnostics, hospitals and clinics will continue to play pivotal roles in meeting the expanding demand for neurodiagnostic services.
Global Neurodiagnostics Market, Segmentation by Geography
In this report, the Global Neurodiagnostics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Neurodiagnostics Market Share (%), by Geographical Region, 2024
The global neurodiagnostics market, segmented geographically into North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America, reflects significant regional variations in healthcare infrastructure, prevalence of neurological disorders, and access to advanced diagnostics. North America holds the largest share in the market, attributed to a high incidence of neurological conditions like Alzheimer’s, Parkinson’s, and epilepsy, coupled with advanced healthcare facilities and widespread availability of neurodiagnostic equipment. The U.S. in particular, with its robust research funding and emphasis on early diagnosis, has become a leader in adopting new technologies, such as artificial intelligence and machine learning in neurodiagnostics. Additionally, favorable reimbursement policies and strong investment in healthcare research further fuel market growth in North America.
Europe follows closely, benefiting from well-established healthcare systems and a growing elderly population susceptible to neurodegenerative diseases. Countries like Germany, France, and the U.K. are significant contributors, driven by government support for neurological research and technological advancements in diagnostics. Europe is also witnessing an increase in public awareness of neurological health, leading to higher demand for neurodiagnostic solutions in both urban and rural healthcare settings. This region places particular emphasis on improving diagnostic accuracy and preventive care, with many initiatives aimed at increasing access to healthcare in underserved communities. The European Union’s focus on innovation and regulatory support for medical devices further strengthens the neurodiagnostics market in this region.
Asia-Pacific is anticipated to experience the fastest growth in the neurodiagnostics market due to its large population, rising prevalence of neurological disorders, and increasing healthcare investments. Countries such as China, India, and Japan are seeing rapid advancements in healthcare infrastructure and expanding access to diagnostic tools. Governments in Asia-Pacific are increasingly investing in healthcare facilities and diagnostic technology to address the growing burden of neurological diseases. Additionally, the rise of telemedicine and mobile health solutions is allowing better access to neurodiagnostic services in remote areas, particularly in India and Southeast Asia. Meanwhile, the Middle East and Africa, along with Latin America, are smaller markets but show promising growth potential due to improving healthcare infrastructure and rising awareness about neurological health. While challenges like limited access to advanced diagnostics remain in these regions, increased government initiatives and partnerships with global neurodiagnostic companies are likely to accelerate market development. Each of these regions demonstrates unique growth factors, collectively driving the global neurodiagnostics market forward.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Neurodiagnostics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Market Drivers, Restraints and Opportunities Analysis.
Drivers- Rising Neurological Disorders
- Advancements in Imaging and Non-Invasive Techniques
- Growing Aging Population-The growing aging population is a major driver in the global neurodiagnostics market, as older adults are significantly more prone to neurological disorders such as Alzheimer’s disease, Parkinson’s disease, stroke, and dementia. As life expectancy continues to rise worldwide, so does the prevalence of age-related neurological conditions, creating an urgent need for advanced diagnostic tools to enable early and accurate detection. This demographic shift is particularly pronounced in regions like North America, Europe, and parts of Asia, where large segments of the population are entering age brackets most vulnerable to neurological decline.
With age-related neurodegenerative diseases expected to become one of the leading causes of disability globally, the demand for neurodiagnostic solutions that facilitate timely intervention is higher than ever. Advanced imaging systems, such as MRI and CT, as well as innovative biomarkers and in vitro diagnostics, are becoming essential in assessing, monitoring, and managing these conditions. Early diagnosis can substantially improve treatment outcomes and quality of life for elderly patients by slowing disease progression and enabling personalized care strategies, further emphasizing the importance of neurodiagnostic tools in geriatric healthcare.
Restraints
- High Cost of Advanced Diagnostic Equipment
- Lack of Skilled Professionals
- Limited Access in Developing Region-Limited access to neurodiagnostic tools in developing regions is a significant barrier to the growth and effectiveness of the global neurodiagnostics market. Many low- and middle-income countries struggle with restricted healthcare infrastructure, insufficient funding, and a lack of advanced medical technologies, which makes it difficult to meet the rising demand for neurological diagnostics. In these areas, patients suffering from neurological conditions like epilepsy, stroke, and Alzheimer’s often face delays in diagnosis or misdiagnoses, leading to worsening health outcomes and limited treatment options. This gap in access to quality diagnostics underscores a need for more affordable and accessible neurodiagnostic solutions tailored to resource-constrained environments.
A primary challenge in these regions is the high cost of advanced neurodiagnostic equipment, such as MRI, CT, and PET scanners, which are expensive to purchase, install, and maintain. Additionally, a shortage of skilled professionals capable of operating these sophisticated machines further restricts access to quality neurodiagnostic services. For instance, rural and remote areas often lack qualified neurologists or technicians, making it nearly impossible for patients to receive timely diagnostics. This professional shortfall contributes to a widening disparity in neurological healthcare access, as many rural patients must travel to urban centers to seek specialized care, which is not always feasible.
Opportunities
- Expansion in Emerging Markets
- Integration of AI and Machine Learning
- Development of Portable and Wearable Devices-The development of portable and wearable neurodiagnostic devices is transforming the global neurodiagnostics market, offering innovative solutions that make neurological monitoring more accessible, convenient, and affordable. These devices, which include portable EEG monitors, wearable brain imaging systems, and mobile EMG tools, are revolutionizing diagnostics by enabling real-time monitoring and data collection outside of traditional clinical settings. By making neurodiagnostics more adaptable to diverse environments, portable and wearable devices are expanding access to quality neurological care, particularly for patients in remote or underserved areas, where access to full-scale diagnostic facilities is often limited.
One of the most significant advantages of portable and wearable neurodiagnostic devices is their potential for continuous monitoring. Unlike standard diagnostic tools that require patients to visit a clinic or hospital, wearable devices allow for long-term data collection in real-life settings, capturing a more comprehensive view of a patient's neurological activity. This is particularly beneficial for conditions like epilepsy, sleep disorders, and migraines, where symptoms may be episodic or occur irregularly. Continuous monitoring not only improves diagnostic accuracy but also helps in tailoring more personalized treatment plans by providing healthcare professionals with a more holistic understanding of a patient’s condition.
Competitive Landscape Analysis
Key players in Global Neurodiagnostics Market include:
- Canon Medical Systems Corporation
- Siemens Healthineers AG
- Koninklijke Philips N.V.
- Thermo Fisher Scientific, Inc.
- FUJIFILM Corporation
- Natus Medical Incorporated (Natus)
- Lifelines Neuro
- Advanced Brain Monitoring, Inc.
- NIHON KOHDEN CORPORATION.
- F. Hoffmann-La Roche Ltd
- GE HealthCare.
- Mitsar Co. LTD.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Technology
- Market Snapshot, By End Use
- Market Snapshot, By Region
- Global Neurodiagnostics Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Rising Neurological Disorders
- Advancements in Imaging and Non-Invasive Techniques
- Growing Aging Population
- Restraints
- High Cost of Advanced Diagnostic Equipment
- Lack of Skilled Professionals
- Limited Access in Developing Region
- Opportunities
- Expansion in Emerging Markets
- Integration of AI and Machine Learning
- Development of Portable and Wearable Devices
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Neurodiagnostics Market, By Technology, 2021 - 2031 (USD Million)
- Neuroimaging Technologies
- In Vitro Diagnostics
- Neuro informatics
- Global Neurodiagnostics Market, ByEnd Use, 2021 - 2031 (USD Million)
- Hospitals
- Clinics
- Global Neurodiagnostics Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Neurodiagnostics Market, By Technology, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Canon Medical Systems Corporation
- Siemens Healthineers AG
- Koninklijke Philips N.V.
- Thermo Fisher Scientific, Inc.
- FUJIFILM Corporation
- Natus Medical Incorporated (Natus)
- Lifelines Neuro
- Advanced Brain Monitoring, Inc.
- NIHON KOHDEN CORPORATION.
- F. Hoffmann-La Roche Ltd
- GE HealthCare.
- Mitsar Co. LTD.
- Company Profiles
- Analyst Views
- Future Outlook of the Market